Cargando…

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis

This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arango, Celso, Ng-Mak, Daisy, Finn, Elaine, Byrne, Aidan, Loebel, Antony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497364/ https://www.ncbi.nlm.nih.gov/pubmed/31758359 http://dx.doi.org/10.1007/s00787-019-01425-2

Ejemplares similares

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
por: Meyer, Jonathan M., et al.
Publicado: (2017)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
por: Meltzer, Herbert Y., et al.
Publicado: (2020)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017)

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)

Antipsychotic treatments; focus on lurasidone
por: Sumiyoshi, Tomiki
Publicado: (2013)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
por: Nasrallah, Henry A., et al.
Publicado: (2014)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
por: Harvey, Philip D., et al.
Publicado: (2016)

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
por: Newcomer, John W., et al.
Publicado: (2016)

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression
por: Singh, Manpreet K., et al.
Publicado: (2023)

Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia
por: Pochiero, Ilena, et al.
Publicado: (2021)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study
por: Takahashi, Michihiro, et al.
Publicado: (2015)

Lurasidone for the Treatment of Irritability Associated with Autistic Disorder
por: Loebel, Antony, et al.
Publicado: (2015)

PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies
por: Potkin, Steven G., et al.
Publicado: (2016)

PS37. Lurasidone in the Treatment of Bipolar Depression: Effect of Baseline Depression Severity on Clinical Outcome
por: Pikalov, Andrei, et al.
Publicado: (2016)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia
por: Danek, Przemysław J., et al.
Publicado: (2022)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone
por: Sood, Shabnam
Publicado: (2017)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial
por: Sinkeviciute, Igne, et al.
Publicado: (2021)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Quantitative Resting State Electroencephalography in Patients with Schizophrenia Spectrum Disorders Treated with Strict Monotherapy Using Atypical Antipsychotics
por: Ozaki, Takashi, et al.
Publicado: (2021)

The clinical utility of lurasidone in schizophrenia: patient considerations
por: Harvey, Philip D
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6lq1ml5pqd53vfcaq8pq2snptl